B7H3/IL13Ra2 Bispecific Armored Chimeric Antigen Receptor T-Cell Therapy Study for Recurrent/Refractory Glioblastoma

Clinical trial NCT07193628 · RECRUITING

Trial details

NCT number: NCT07193628
Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Refractory Glioblastoma Recurrent Glioblastoma

Start date: 2025-09-26
Primary completion: 2027-12-31
Enrollment: 14

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.